<DOC>
	<DOCNO>NCT00983138</DOCNO>
	<brief_summary>This non-controlled multicentre phase II study design assess safety describe ( relation child high age ) pharmacodynamics recombinant ASNase ( rASNase ) first-line treatment infant ( &lt; 1 year age diagnosis ) de novo acute lymphoblastic leukaemia</brief_summary>
	<brief_title>Efficacy Safety Recombinant Asparaginase Infants With Previously Untreated Acute Lymphoid Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Previously untreated Tlineage precursor Blineage ALL biphenotypic leukaemia accord EGIL criterion . Morphological verification diagnosis , confirm cyto¬chemistry immunophenotyping . Age &lt; 1 year diagnosis . Written inform consent parent legally authorise guardian patient . Treatment accord protocol INTERFANT 06 Mature Blineage ALL , define immunophenotypical presence surface immunoglobulin ( 8 ; 14 ) breakpoint BALL . The presence ( 9 ; 22 ) ( q34 ; q11 ) bcrabl fusion leukaemic cell . Systemic use corticosteroid less 4 week diagnosis . Patients receive corticosteroid aerosol eligible . Known allergy ASNase preparation . Preexisting know coagulopathy ( e.g . haemophilia ) . Preexisting pancreatitis . Liver insufficiency ( bilirubin &gt; 50 µmol/L ; SGOT/SGPT &gt; 10 x upper limit normal ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>364 Days</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>